Managing Serum Potassium During Esaxerenone Treatment: Clinical Considerations and Evidence-Based Strategies

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has demonstrated efficacy in the management of hypertension and chronic kidney disease (CKD). However, the risk of hyperkalemia remains a significant clinical concern during therapy. This review synthesizes current evidence regarding serum potassium management in patients treated with esaxerenone, highlighting epidemiological data, underlying mechanisms, risk factors, clinical features, diagnostic strategies, and evidence-based management. Practical recommendations are provided for clinicians to optimize outcomes and minimize complications associated with altered potassium homeostasis.

Introduction

Esaxerenone represents an important advancement in the pharmacologic armamentarium for hypertension and CKD. As a selective non-steroidal MRA, esaxerenone offers comparable antihypertensive and renoprotective benefits to its predecessors, with an improved safety profile. Nevertheless, similar to other MRAs, esaxerenone is associated with the risk of hyperkalemia, which can be life-threatening if not properly monitored and managed. Understanding the epidemiology, pathophysiology, and practical strategies for serum potassium management is essential for clinicians to ensure patient safety and maximize therapeutic efficacy.

Epidemiology / Disease Burden

Hyperkalemia is a well-recognized complication of MRA therapy, particularly in populations with comorbid CKD, diabetes, or heart failure. Clinical trials evaluating esaxerenone have reported hyperkalemia (serum potassium >5.5 mmol/L) in 5–12% of treated patients, with severe cases (>6.0 mmol/L) being rare but clinically relevant. The risk is heightened in elderly individuals, those with reduced estimated glomerular filtration rate (eGFR), and patients on concomitant renin-angiotensin-aldosterone system (RAAS) inhibitors. Given the growing use of MRAs for cardiometabolic indications, the burden of hyperkalemia is expected to increase.

Pathophysiology

Esaxerenone exerts its effects by antagonizing mineralocorticoid receptors in the distal nephron, diminishing aldosterone-mediated sodium reabsorption and potassium excretion. While this results in blood pressure reduction and organ protection, it impairs renal potassium excretion, predisposing to hyperkalemia. The risk is exacerbated in the presence of impaired renal function, reduced distal sodium delivery, or concomitant agents that decrease aldosterone activity. Understanding this mechanism is central to risk stratification and targeted monitoring.

Risk Factors

Several patient-specific and therapy-related factors increase susceptibility to hyperkalemia during esaxerenone treatment. Key risk factors include advanced age, reduced eGFR (<45 mL/min/1.73m2), diabetes mellitus, baseline serum potassium >4.5 mmol/L, concomitant use of RAAS inhibitors, potassium-sparing diuretics, and high dietary potassium intake. Identifying these risk factors before and during treatment allows for tailored management and mitigation strategies.

Clinical Features

Hyperkalemia is often asymptomatic in early stages but can progress to manifest neuromuscular symptoms (e.g., muscle weakness, paresthesias) and cardiac manifestations (e.g., arrhythmias, conduction disturbances) at higher levels. Electrocardiographic changes such as peaked T waves, widened QRS complexes, and sine wave patterns signal impending risk of cardiac arrest. Vigilant monitoring for these signs is imperative, especially in high-risk individuals.

Diagnosis

Routine measurement of serum potassium is the cornerstone of diagnosis and monitoring. Baseline assessment is warranted prior to initiation of esaxerenone, with repeat measurements at 1–2 weeks, 1 month, and periodically thereafter based on risk profile. Laboratory evaluation should be interpreted in the context of renal function, concomitant medications, and dietary intake. Pseudohyperkalemia due to hemolysis or specimen handling should be excluded before escalating therapy or interventions.

Treatment & Management

Management of serum potassium during esaxerenone therapy involves a combination of preventive, monitoring, and therapeutic strategies. For mild elevations (5.5–6.0 mmol/L), stepwise interventions include dietary potassium restriction, review of concomitant medications, and consideration of dose reduction or temporary discontinuation of esaxerenone. Severe hyperkalemia (>6.0 mmol/L) necessitates prompt cessation of esaxerenone, urgent correction with pharmacologic agents (e.g., sodium polystyrene sulfonate, patiromer, sodium zirconium cyclosilicate), and hospitalization in the presence of ECG changes. Reinitiation may be considered once potassium normalizes, with closer surveillance.

Recent Advances / Emerging Therapies

Recent trials suggest that esaxerenone has a relatively lower risk of hyperkalemia compared to steroidal MRAs, possibly due to its high selectivity and minimal off-target effects. The emergence of novel potassium binders (e.g., patiromer, sodium zirconium cyclosilicate) provides additional tools for chronic management, enabling safer continuation of MRA therapy in high-risk patients. Ongoing studies are evaluating protocolized monitoring and telemedicine interventions to enhance early detection and intervention.

Guideline Recommendations

Current hypertension and CKD guidelines emphasize careful patient selection, baseline potassium assessment, and individualized monitoring schedules during MRA therapy. Esaxerenone should be initiated at lower doses in patients with reduced renal function, with dose titration guided by serial potassium measurements. Guidelines recommend avoiding unnecessary potassium supplements and discontinuing or adjusting interacting medications. Patient education on dietary potassium and symptom recognition is integral to risk mitigation.

Conclusion

Effective management of serum potassium is vital for the safe and successful use of esaxerenone in clinical practice. Through judicious patient selection, vigilant monitoring, rapid intervention, and integration of novel therapeutic options, clinicians can minimize the risk of hyperkalemia and optimize cardiorenal outcomes. Continued research and multidisciplinary collaboration will further refine best practices and ensure patient safety in this evolving therapeutic landscape.